# Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

> **NCT07267247** · — · COMPLETED · sponsor: **Taichung Veterans General Hospital** · enrollment: 100 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
- Drug-Related Side Effects and Adverse Reactions (MeSH Term)
- Egfr Tyrosine Kinase Inhibitor
- Cardiotoxicity

## Interventions

- **DRUG:** EGFR-TKI
- **OTHER:** EGFR tyrosine kinase inhibitor

## Key facts

- **NCT ID:** NCT07267247
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07267247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07267247, "Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07267247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*